CY1112917T1 - Υγρες στοματικες συνθεσεις - Google Patents
Υγρες στοματικες συνθεσειςInfo
- Publication number
- CY1112917T1 CY1112917T1 CY20121100552T CY121100552T CY1112917T1 CY 1112917 T1 CY1112917 T1 CY 1112917T1 CY 20121100552 T CY20121100552 T CY 20121100552T CY 121100552 T CY121100552 T CY 121100552T CY 1112917 T1 CY1112917 T1 CY 1112917T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aqueous suspension
- simvastatin
- agent
- oral compositions
- liquid oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
- A63B21/00—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
- A63B21/02—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using resilient force-resisters
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
- A63B2225/00—Miscellaneous features of sport apparatus, devices or equipment
- A63B2225/09—Adjustable dimensions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Εναιώρημα που είναι κατάλληλο για στοματική χορήγηση, που περιλαμβάνει σιμβαστατίνη, τουλάχιστον ένα παράγοντα εναιώρησης και τουλάχιστον ένα συντηρητικό, όπου τουλάχιστον το 90% των σωματιδίων της σιμβαστατίνης είναι μικρότερα από 100 μm σε διάμετρο. Η παρούσα εφεύρεση περιλαμβάνει επίσης τις χρήσεις του εναιωρήματος και τις μεθόδους παραγωγής του εναιωρήματος.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74565306P | 2006-04-26 | 2006-04-26 | |
EP07732588A EP2018153B1 (en) | 2006-04-26 | 2007-04-26 | Liquid oral compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112917T1 true CY1112917T1 (el) | 2016-04-13 |
Family
ID=38520565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100552T CY1112917T1 (el) | 2006-04-26 | 2012-06-18 | Υγρες στοματικες συνθεσεις |
Country Status (13)
Country | Link |
---|---|
US (2) | US9597289B2 (el) |
EP (1) | EP2018153B1 (el) |
JP (1) | JP2009534459A (el) |
CN (1) | CN101431982A (el) |
AT (1) | ATE552825T1 (el) |
AU (1) | AU2007245410A1 (el) |
CY (1) | CY1112917T1 (el) |
DK (1) | DK2018153T3 (el) |
ES (1) | ES2385752T3 (el) |
PL (1) | PL2018153T3 (el) |
PT (1) | PT2018153E (el) |
SI (1) | SI2018153T1 (el) |
WO (1) | WO2007125339A1 (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2018153T3 (da) * | 2006-04-26 | 2012-07-23 | Rosemont Pharmaceuticals Ltd | Flydende orale sammensætninger |
GB2497728A (en) * | 2011-12-14 | 2013-06-26 | Londonpharma Ltd | Statin formulations for transmucosal delivery |
CN104586761A (zh) * | 2013-10-30 | 2015-05-06 | 上海信谊药厂有限公司 | 辛伐他汀纳米混悬剂及其制备方法 |
JP6832195B2 (ja) * | 2016-03-03 | 2021-02-24 | ライオン株式会社 | 経口液剤及び経口固形剤 |
WO2017212409A1 (en) * | 2016-06-08 | 2017-12-14 | Ftf Pharma Private Limited | A novel pharmaceutical composition of a lipid lowering compound |
GB201704687D0 (en) | 2017-03-24 | 2017-05-10 | Wockhardt Uk Ltd | Pharmaceutical composition of simvastatin or salt thereof |
CN108403630A (zh) * | 2018-05-31 | 2018-08-17 | 佛山市南海东方澳龙制药有限公司 | 混悬剂及其制备方法 |
CN110812326B (zh) * | 2019-11-04 | 2022-04-22 | 黑龙江省农业科学院畜牧兽医分院 | 一种辛伐他汀混悬乳剂及其制备方法和应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4994273A (en) | 1987-11-02 | 1991-02-19 | Merck & Co., Inc. | Solubility modulated drug delivery device |
US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
US5948438A (en) * | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
CZ127198A3 (cs) | 1995-11-02 | 1998-12-16 | Warner-Lambert Company | Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob |
DE19541260A1 (de) | 1995-11-06 | 1997-05-07 | Lohmann Therapie Syst Lts | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
US20050038102A1 (en) | 1997-10-14 | 2005-02-17 | Brigham And Womens Hospital | Upregulation of type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors |
EP0940395A1 (en) | 1998-03-05 | 1999-09-08 | Synthon B.V. | Process for producing simvastatin and/or its derivatives |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
CA2240983A1 (en) | 1998-06-18 | 1999-12-18 | Yong Tao | Process to manufacture simvastatin and intermediates |
US20010006656A1 (en) | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
US6696086B1 (en) | 1999-09-10 | 2004-02-24 | Lek Pharmaceuticals D.D. | Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation |
US6573392B1 (en) | 1999-11-11 | 2003-06-03 | Biocon India Limited | Process for manufacturing simvastatin and the novel intermediates |
FR2801508B1 (fr) | 1999-11-29 | 2003-11-14 | Oreal | Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee |
US6534537B2 (en) | 2000-01-07 | 2003-03-18 | Kenneth Weisman | Use of HMG-COA reductase inhibitors to prevent and treat BPH |
US6576775B1 (en) | 2000-03-30 | 2003-06-10 | Cheil Jedang Corporation | Process for producing simvastatin |
US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
WO2002009697A1 (en) | 2000-07-27 | 2002-02-07 | Plus Chemicals, B.V | Highly purified simvastatin compositions |
DE10057648A1 (de) | 2000-11-21 | 2002-06-06 | Univ Jw Goethe Frankfurt Main | Verwendung von Inhibitoren von 3-Hydroxyl-3-methylglutaryl-Coenzym-A-Reduktase |
WO2002047682A1 (fr) | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Composition ameliorant les lipides sanguins |
PT1363516E (pt) | 2001-02-27 | 2005-11-30 | Chong Kun Dang Pharm Corp | Um processo melhorado para a preparacao da sinvastatina |
BR0207930A (pt) * | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Composições farmacêuticas lìquidas com sabor mascarado |
FR2821745B1 (fr) * | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | Granules et granules enrobes au gout masque |
WO2002094803A1 (en) | 2001-05-18 | 2002-11-28 | Aurobindo Pharma Limited | A process for lactonization to produce highly pure simvastatin |
US6797831B2 (en) | 2001-05-18 | 2004-09-28 | Aurobindo Pharma Limited | Process for lactonization to produce simvastatin |
EP1395254B1 (en) * | 2001-06-12 | 2007-04-04 | Galephar M/F | Oral pharmaceutical composition containing a statin derivative |
FR2827770B1 (fr) | 2001-07-27 | 2005-08-19 | Gattefosse Ets Sa | Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
KR100407758B1 (ko) | 2001-08-27 | 2003-12-01 | 씨제이 주식회사 | 스타틴의 제조에 있어서 락톤화 방법 |
US20030065019A1 (en) | 2001-09-19 | 2003-04-03 | Francois Mach | Treatment of rheumatoid arthritis with statins (HMG-CoA reductase inhibitors) |
US6709600B2 (en) | 2001-09-21 | 2004-03-23 | The Regents Of The University Of California | Method for removing organic liquids from aqueous solutions and mixtures |
US20040142902A1 (en) | 2001-11-08 | 2004-07-22 | Struijker- Boudier Harry A.J. | Implant dosage form and use thereof for the delivery of a cholosterol lowering agent |
US20040018248A1 (en) | 2001-11-29 | 2004-01-29 | Adrianne Bendich | Composition containing statins and calcium for improved cardiovascular health |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
KR20040073493A (ko) * | 2001-12-20 | 2004-08-19 | 파마시아 코포레이션 | 경구 투여용 제약 현탁액 |
US20030162827A1 (en) | 2002-01-30 | 2003-08-28 | Suresh Venkataram | HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition |
ES2192988B1 (es) | 2002-02-28 | 2005-02-16 | Jose Manuel Quesada Gomez | Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas. |
US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
US6603022B1 (en) | 2002-05-10 | 2003-08-05 | Biocon India Limited | Process for manufacturing Simvastatin and novel intermediates thereof |
WO2003103640A1 (en) | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
WO2004006919A1 (ja) * | 2002-07-11 | 2004-01-22 | Sankyo Company, Limited | 血中脂質改善又は血中ホモシステイン低下のための医薬組成物 |
US20050182106A1 (en) | 2002-07-11 | 2005-08-18 | Sankyo Company, Limited | Medicinal composition for mitigating blood lipid or lowering blood homocysteine |
US20050182036A1 (en) | 2002-08-02 | 2005-08-18 | Sankyo Company, Limited | Medicinal composition containing an HMG-CoA reductase inhibitor |
US20050187204A1 (en) | 2002-08-08 | 2005-08-25 | Sankyo Company, Limited | Medicinal composition for lowering blood lipid level |
JP2006503023A (ja) | 2002-09-03 | 2006-01-26 | バイオヴェイル ラボラトリーズ インコーポレイテッド | スタチン薬物の放出調節ための医薬品製剤および方法 |
WO2004024073A2 (en) | 2002-09-11 | 2004-03-25 | The Board Of Trustees Of The University Of Arkansas | Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin |
CN100486572C (zh) * | 2002-11-04 | 2009-05-13 | 饶品昌 | 他汀类药物新剂型 |
US6995277B2 (en) | 2003-02-11 | 2006-02-07 | Plus Chemicals, B.V. | Process for preparing simvastatin having controlled ranges of simvastatin dimer content |
US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
US20050192340A1 (en) | 2003-11-05 | 2005-09-01 | Moshe Flashner-Barak | Simvastatin formulations and methods of making same |
EP1722780A4 (en) | 2003-11-26 | 2008-12-17 | Univ Duke | METHOD FOR PREVENTING OR TREATING GLAUCOMA |
EP1563837A1 (en) | 2004-02-03 | 2005-08-17 | Ferrer Internacional, S.A. | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
WO2005105069A1 (en) | 2004-04-26 | 2005-11-10 | Alcon, Inc. | Statins for the treatment of ocular hypertension and glaucoma |
US20050267197A1 (en) | 2004-05-25 | 2005-12-01 | Roger Berlin | Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses |
JP2006022039A (ja) * | 2004-07-08 | 2006-01-26 | Towa Yakuhin Kk | 高い安定性を有するシンバスタチン固形製剤 |
ES2255426B1 (es) | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
FR2898492B1 (fr) * | 2006-03-15 | 2008-06-06 | Pierre Fabre Medicament Sa | Comprimes orodispersibles de domperidone |
DK2018153T3 (da) * | 2006-04-26 | 2012-07-23 | Rosemont Pharmaceuticals Ltd | Flydende orale sammensætninger |
EP2197416A1 (en) * | 2007-10-09 | 2010-06-23 | Novartis Ag | Pharmaceutical formulation of valsartan |
-
2007
- 2007-04-26 DK DK07732588.4T patent/DK2018153T3/da active
- 2007-04-26 PL PL07732588T patent/PL2018153T3/pl unknown
- 2007-04-26 CN CNA2007800150702A patent/CN101431982A/zh active Pending
- 2007-04-26 AU AU2007245410A patent/AU2007245410A1/en not_active Abandoned
- 2007-04-26 US US12/298,451 patent/US9597289B2/en active Active
- 2007-04-26 WO PCT/GB2007/001552 patent/WO2007125339A1/en active Application Filing
- 2007-04-26 SI SI200730938T patent/SI2018153T1/sl unknown
- 2007-04-26 AT AT07732588T patent/ATE552825T1/de active
- 2007-04-26 ES ES07732588T patent/ES2385752T3/es active Active
- 2007-04-26 JP JP2009507170A patent/JP2009534459A/ja not_active Withdrawn
- 2007-04-26 EP EP07732588A patent/EP2018153B1/en active Active
- 2007-04-26 PT PT07732588T patent/PT2018153E/pt unknown
-
2012
- 2012-06-18 CY CY20121100552T patent/CY1112917T1/el unknown
-
2017
- 2017-02-03 US US15/423,710 patent/US10300041B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2018153B1 (en) | 2012-04-11 |
US9597289B2 (en) | 2017-03-21 |
SI2018153T1 (sl) | 2012-08-31 |
ES2385752T3 (es) | 2012-07-31 |
PT2018153E (pt) | 2012-07-04 |
EP2018153A1 (en) | 2009-01-28 |
AU2007245410A1 (en) | 2007-11-08 |
JP2009534459A (ja) | 2009-09-24 |
US20170143669A1 (en) | 2017-05-25 |
US20090311330A1 (en) | 2009-12-17 |
ATE552825T1 (de) | 2012-04-15 |
US10300041B2 (en) | 2019-05-28 |
CN101431982A (zh) | 2009-05-13 |
PL2018153T3 (pl) | 2012-09-28 |
DK2018153T3 (da) | 2012-07-23 |
WO2007125339A1 (en) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
MX2009004767A (es) | Preparacion liquida que comprende un complejo de pimobendan y ciclodextrina. | |
RS54769B1 (sr) | Visoko koncentrovane farmaceutske formulacije koje sadrže anti-cd20 antitelo | |
NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
WO2007027941A3 (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
TW200744677A (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
MX2010003923A (es) | Formulacion farmaceutica de valsartan. | |
TW200600118A (en) | Pharmaceutical suspension composition | |
RS52913B (en) | SUBcutaneous FORMULATION OF ANTI-HER2 ANTIBODIES | |
MX348936B (es) | Formulaciones de antibioticos, dosis unitarias, equipos y metodos. | |
MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
JP2009531457A5 (el) | ||
MA33044B1 (fr) | Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
MX2010005198A (es) | Composiciones liquidas que comprenden valsartan. | |
FR2924024B1 (fr) | Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse | |
WO2008026048A3 (en) | Stable injectable pharmaceutical compositions of docetaxel | |
EA200801614A1 (ru) | Фармацевтическая композиция, содержащая монтелукаст | |
RS54140B1 (en) | USE OF 24-ORDER | |
WO2008114859A1 (ja) | ピラゾール誘導体を含有する医薬組成物 | |
IL186058A0 (en) | Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt | |
CY1120050T1 (el) | Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων | |
MX2014009660A (es) | Formulacion de anticuerpo anti-selectina p. | |
MX2010001092A (es) | Composicion farmaceutica liquida estable basada en trazodona. |